RadNet (RDNT) Receiving Somewhat Favorable News Coverage, Study Finds

News coverage about RadNet (NASDAQ:RDNT) has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. RadNet earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 44.524804835931 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Shares of RadNet traded up $0.35, hitting $15.40, during trading hours on Thursday, MarketBeat Ratings reports. The company’s stock had a trading volume of 225,600 shares, compared to its average volume of 283,363. RadNet has a 1-year low of $7.45 and a 1-year high of $15.45. The firm has a market capitalization of $726.01 million, a P/E ratio of 53.10, a PEG ratio of 5.15 and a beta of 0.40. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 4.90.

RadNet (NASDAQ:RDNT) last released its quarterly earnings data on Wednesday, May 9th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.19). RadNet had a positive return on equity of 18.77% and a negative net margin of 0.66%. The business had revenue of $231.39 million during the quarter, compared to analyst estimates of $234.32 million. During the same period in the previous year, the company earned ($0.03) EPS. RadNet’s revenue was up 1.0% on a year-over-year basis. research analysts expect that RadNet will post 0.37 EPS for the current fiscal year.

Several brokerages recently commented on RDNT. FIX started coverage on shares of RadNet in a research report on Wednesday, March 14th. They set a “strong-buy” rating and a $15.00 price target for the company. ValuEngine raised shares of RadNet from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Jefferies Financial Group set a $14.00 price objective on shares of RadNet and gave the stock a “buy” rating in a research report on Thursday, March 8th. BidaskClub raised shares of RadNet from a “hold” rating to a “buy” rating in a research report on Wednesday, March 14th. Finally, Zacks Investment Research lowered shares of RadNet from a “buy” rating to a “hold” rating in a research report on Friday, March 23rd. One investment analyst has rated the stock with a hold rating, three have given a buy rating and two have given a strong buy rating to the company. RadNet has a consensus rating of “Buy” and an average target price of $14.75.

In related news, insider Norman R. Hames sold 15,000 shares of the firm’s stock in a transaction on Friday, May 18th. The shares were sold at an average price of $13.04, for a total transaction of $195,600.00. Following the completion of the sale, the insider now directly owns 348,450 shares of the company’s stock, valued at approximately $4,543,788. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jeffrey L. Linden sold 10,000 shares of the firm’s stock in a transaction on Monday, June 11th. The shares were sold at an average price of $12.97, for a total transaction of $129,700.00. Following the sale, the insider now directly owns 912,001 shares of the company’s stock, valued at $11,828,652.97. The disclosure for this sale can be found here. Insiders sold 85,000 shares of company stock valued at $1,117,750 in the last three months. Company insiders own 7.56% of the company’s stock.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Insider Buying and Selling by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply